New Drug CD47 Could Potentially Shrink and Cure All Tumors


New research points that there could be a single drug that could shrink or cure all types of cancer, whether it’s breast, ovary, colon, bladder, brain, or liver. The treatment uses an antibody that blocks the ‘do not eat’ signal that’s usually displayed on tumor cells and coaxes the immune system to destroy cancer cells.

Leukemia cells produce higher levels of the CD47 protein than healthy cells. It’s a marker that will block the immune system from destroying healthy blood cells. Cancers take advantage of this by using it to trick the immune system into ignoring them.


CD47  is found on every human primary tumor that the team has tested. The researchers transplanted human tumors into mice. Once the rodents were treated with anti-CD47, the tumors shrank and did not spread.

They showed that even after the tumor had taken hold, the antibody could cure or slow the growth of the tumor. The findings were published in the journal the Proceedings of the National Academy of Sciences.


More research is needed to see whether this antibody will work on humans the same way. The researchers also need to find out how the CD47 antibodies would mesh with existing treatments. It’s possible that it wouldn’t work well in patients using chemotherapy, since it causes normal cells to produce more CD47.

The research team has received a grant of $20 million from the California Institute for Regenerative Medicine to move their drug into human trials.

[via Science]

3 Comments on "New Drug CD47 Could Potentially Shrink and Cure All Tumors"

  1. Raymond Ogbole | July 3, 2014 at 6:04 pm | Reply

    Am interested in human trial; how can I participate in this project. Can I have access to the CD47 antibody drug?

  2. What’s the latest with Anti-CD47 technology?
    Where’s the clinical trials?

  3. pat shellabarger | October 11, 2018 at 3:43 pm | Reply

    would like to know about cd47, will it help pancreatic cancer?

Leave a comment

Email address is optional. If provided, your email will not be published or shared.